Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs

Antimicrobial resistance, the so-called <i>silent pandemic</i>, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	José Manuel Ezquerra-Aznárez, Pedro E. Almeida da Silva, José A. Aínsa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	antituberculosis drugs antiparasitic drugs drug resistance repurposing drug discovery Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/f7705edc6599407fbc05f8f9286b2d27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7705edc6599407fbc05f8f9286b2d27
record_format	dspace
spelling	oai:doaj.org-article:f7705edc6599407fbc05f8f9286b2d272021-11-25T18:25:13ZOvercoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs10.3390/microorganisms91123352076-2607https://doaj.org/article/f7705edc6599407fbc05f8f9286b2d272021-11-01T00:00:00Zhttps://www.mdpi.com/2076-2607/9/11/2335https://doaj.org/toc/2076-2607Antimicrobial resistance, the so-called <i>silent pandemic</i>, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel anti-tuberculosis drugs is specially challenging because of the intricate biology of its causative agent, <i>Mycobacterium tuberculosis</i>. The repurposing of medicines has arisen in recent years as a fast, low-cost, and efficient strategy to identify novel biomedical applications for already approved drugs. This review is focused on anti-parasitic drugs that have additionally demonstrated certain levels of anti-tuberculosis activity; along with this, natural products with a dual activity against parasites and against <i>M. tuberculosis</i> are discussed. A few clinical trials have tested antiparasitic drugs in tuberculosis patients, and have revealed effective dose and toxicity issues, which is consistent with the natural differences between tuberculosis and parasitic infections. However, through medicinal chemistry approaches, derivatives of drugs with anti-parasitic activity have become successful drugs for use in tuberculosis therapy. In summary, even when the repurposing of anti-parasitic drugs for tuberculosis treatment does not seem to be an easy job, it deserves attention as a potential contributor to fuel the anti-tuberculosis drug pipeline.José Manuel Ezquerra-AznárezPedro E. Almeida da SilvaJosé A. AínsaMDPI AGarticleantituberculosis drugsantiparasitic drugsdrug resistancerepurposingdrug discoveryBiology (General)QH301-705.5ENMicroorganisms, Vol 9, Iss 2335, p 2335 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antituberculosis drugs antiparasitic drugs drug resistance repurposing drug discovery Biology (General) QH301-705.5
spellingShingle	antituberculosis drugs antiparasitic drugs drug resistance repurposing drug discovery Biology (General) QH301-705.5 José Manuel Ezquerra-Aznárez Pedro E. Almeida da Silva José A. Aínsa Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
description	Antimicrobial resistance, the so-called <i>silent pandemic</i>, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel anti-tuberculosis drugs is specially challenging because of the intricate biology of its causative agent, <i>Mycobacterium tuberculosis</i>. The repurposing of medicines has arisen in recent years as a fast, low-cost, and efficient strategy to identify novel biomedical applications for already approved drugs. This review is focused on anti-parasitic drugs that have additionally demonstrated certain levels of anti-tuberculosis activity; along with this, natural products with a dual activity against parasites and against <i>M. tuberculosis</i> are discussed. A few clinical trials have tested antiparasitic drugs in tuberculosis patients, and have revealed effective dose and toxicity issues, which is consistent with the natural differences between tuberculosis and parasitic infections. However, through medicinal chemistry approaches, derivatives of drugs with anti-parasitic activity have become successful drugs for use in tuberculosis therapy. In summary, even when the repurposing of anti-parasitic drugs for tuberculosis treatment does not seem to be an easy job, it deserves attention as a potential contributor to fuel the anti-tuberculosis drug pipeline.
format	article
author	José Manuel Ezquerra-Aznárez Pedro E. Almeida da Silva José A. Aínsa
author_facet	José Manuel Ezquerra-Aznárez Pedro E. Almeida da Silva José A. Aínsa
author_sort	José Manuel Ezquerra-Aznárez
title	Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
title_short	Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
title_full	Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
title_fullStr	Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
title_full_unstemmed	Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
title_sort	overcoming the prokaryote/eukaryote barrier in tuberculosis treatment: a prospect for the repurposing and use of antiparasitic drugs
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f7705edc6599407fbc05f8f9286b2d27
work_keys_str_mv	AT josemanuelezquerraaznarez overcomingtheprokaryoteeukaryotebarrierintuberculosistreatmentaprospectfortherepurposinganduseofantiparasiticdrugs AT pedroealmeidadasilva overcomingtheprokaryoteeukaryotebarrierintuberculosistreatmentaprospectfortherepurposinganduseofantiparasiticdrugs AT joseaainsa overcomingtheprokaryoteeukaryotebarrierintuberculosistreatmentaprospectfortherepurposinganduseofantiparasiticdrugs
_version_	1718411235352903680

Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs

Ejemplares similares